Tower Research Capital LLC TRC Has $547,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Tower Research Capital LLC TRC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 419.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,075 shares of the biopharmaceutical company's stock after buying an additional 46,886 shares during the period. Tower Research Capital LLC TRC's holdings in Amicus Therapeutics were worth $547,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Summit Investment Advisors Inc. lifted its position in Amicus Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock valued at $289,000 after purchasing an additional 1,280 shares during the last quarter. Xponance Inc. grew its holdings in shares of Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 2,249 shares in the last quarter. Covestor Ltd increased its holdings in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares during the period. KBC Group NV grew its holdings in shares of Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after acquiring an additional 3,120 shares in the last quarter. Finally, Swiss National Bank increased its position in Amicus Therapeutics by 0.7% in the 4th quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock worth $4,121,000 after purchasing an additional 3,200 shares during the last quarter.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $6.67. The company had a trading volume of 6,371,892 shares, compared to its average volume of 2,687,112. The stock has a market cap of $2.05 billion, a PE ratio of -37.06, a P/E/G ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 1-year low of $6.20 and a 1-year high of $12.65. The business's 50 day simple moving average is $7.95 and its two-hundred day simple moving average is $9.30. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on FOLD. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group reduced their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.